We’ve got news for you!
Follow us on our mission to lead the change towards better and more sustainable products in the new era of biomaterials. Here you will find a summary of our latest news and press releases. If you have any further questions please reach out to:
Isabel Rosenberger
Senior Manager Marketing & Communication
E-Mail: pr@amsilk.com
Tel: (+49) 89 5795393-0
AMSilk GmbH (“AMSilk”), the world’s first industrial supplier of bio-fabricated silk protein materials, today announced it has successfully raised an additional EUR 25 million in an extended Series C financing led by existing investor ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital.
Creating a better future with biotechnology - this vision is shared by BRAIN Biotech AG (BRAIN Biotech), a leader in the development and manufacture of bio-based solutions and products for industry, and AMSilk GmbH (AMSilk), the world's first industrial supplier of innovative biomaterials for more sustainable applications in the textile, medical and consumer goods industries.
Leaders from across the world will convene at VISION 2045 Summit which takes place alongside COP27 (the U.N. Climate Change Conference) in November. AMSilk will be attending and participating in a panel discussion at the Vision 2045 Summit on 'Commerce and Industry: What's Next?'
VISION 2045 is a comprehensive campaign by TBD Media Group that highlights how companies around the world are making the 17 United Nations Goals, first and foremost the key principles of sustainability and social change, an integral part of corporate action.
Expanding biotech laboratory, pilot plants and office space, AMSilk embarks on the next stage of its journey to provide biofabricated silk materials across the world.
AMSilk, a world leader in supplying innovative high-performance bio-based silk materials, today announces plans to scale-up production capacity by several thousand tons a year and expand its production network outside of Europe.
Klaus will lead the scale-up of AMSilk's protein production with existing CMOs. Klaus will be responsible for developing and implementing the future AMSilk strategy for protein production, including the development of capacities and new CMOs worldwide. Klaus brings more than 25 years’ biotechnology experience in global operations
Repellence properties of silk coatings reduced microbial adherence up to 99.7% in comparison to uncoated silicone surfaces. Spider silk coatings have the potential to prevent inflammation and to reduce post-operative complications of implants.
The use of a biotechnology-based and certified-vegan silk-like fabric marks a first in the automotive sector. Partnership with market leader underscores application potential of AMSilk’s technology.
Arne Treinies, an experienced Finance Executive, has joined the company's leadership team as Chief Financial Officer and Managing Director as of September 1st, 2021.